麻豆视频

Global Dairy Enzymes Market Trends and Insights

Growing prevalence of lactose intolerance fueling enzyme adoption

The global prevalence of lactose intolerance serves as a key driver for the adoption of lactase enzymes in dairy manufacturing processes. According to the World Popualtion Review, countries with highest lactose intolerance in 2025 were South Korea, Yemen, Ghana, and Malawi at 100%, and Solomon Islands with 99%. The FDA's Substances Added to Food inventory includes a range of enzymes relevant to dairy applications, highlighting regulatory acknowledgment of their safety and efficacy in addressing lactose intolerance^{[1]Source: United States Food and Drug Administration, "Substances Added to Food (formerly EAFUS)", usda.gov}. This widespread physiological condition has transitioned from being a niche health issue to a mainstream market opportunity, with regional demand for enzyme-treated dairy products varying significantly due to demographic differences. In developed markets, the aging population further fuels growth, as lactose malabsorption tends to increase with age. This demographic shift underscores the importance of enzyme-treated dairy products for older adults who rely on dairy for essential nutrients. Additionally, recent regulatory advancements, such as the approval of lactase enzymes for dietary supplement applications, emphasize the need for a well-documented history of safe use for enzyme ingredients. The growing consumer awareness of lactose intolerance management, coupled with regulatory support for safe enzyme applications in food processing, is driving the shift toward enzyme-based solutions, solidifying their role in the evolving dairy market.

Enzyme use in yogurt and cheese manufactuing enhancing yield and texture

Yogurt and cheese production has progressed significantly, moving beyond basic coagulation processes to incorporate advanced techniques aimed at optimizing texture and maximizing yield. The USDA's technical report on enzymes in organic food production provides a comprehensive overview of enzymes sourced from edible plants, fungi, and bacteria, emphasizing their critical roles in fermentation and the necessity of using non-genetically modified organisms to meet organic production standards. Innovations in enzyme formulations now enable precise control over proteolysis during cheese aging, allowing manufacturers to significantly reduce ripening times while maintaining high-quality standards. These advancements have a direct impact on improving production efficiency, reducing costs, and optimizing inventory management. Additionally, the European Food Safety Authority has strengthened its guidance on food enzymes, introducing specific safety evaluation requirements and tools such as the Food Enzyme Intake Model to accurately estimate dietary exposure to food enzymes. Recent advancements in enzyme applications are focused on enhancing product stability and quality while ensuring compliance with stringent regulatory frameworks for food safety and consumer protection, addressing both industry and consumer needs effectively.

Expansion of functional and fortified dairy product lines

The functional dairy segment is witnessing robust growth as manufacturers increasingly utilize enzyme technologies to develop products with improved nutritional profiles and enhanced health benefits. A significant regulatory milestone was achieved when China's National Health Commission approved 2'-fucosyllactose (2'-FL), a human milk oligosaccharide, for use in infant formula^{[2]Source: U.S Department of Agriculture, "NHC Approves New Food Materials and Additives - Including GMM Derived Enzymes", apps.fas.usda.gov}. This approval validates the safety and efficacy of enzyme-derived functional ingredients and reflects China's growing regulatory acceptance of enzyme technologies in functional dairy applications. Additionally, the accelerated approval process in China highlights a favorable regulatory environment for innovation in this space. In India, the Food Safety and Standards Authority has introduced comprehensive regulations for infant nutrition products, fostering opportunities for the application of specialized enzymes in formula manufacturing while ensuring safety and nutritional adequacy. The rising consumer demand for clean-label products is further driving advancements in enzyme applications. These innovations aim to replace chemical additives with enzyme-based solutions that maintain product functionality and extend shelf life, supported by regulatory frameworks that emphasize stringent safety and efficacy standards for enzyme approvals.

Shift toward sustainable and eco-friendly processing solutions

Sustainability imperatives are driving significant changes in enzyme selection and application strategies within dairy processing operations. The USDA's guidelines for enzymes in organic production emphasize the critical role of non-genetically modified organisms and sustainable production practices, reflecting a broader industry trend toward environmentally friendly and cleaner processing solutions. Additionally, the European Commission's evaluation of the biotechnology industry's competitiveness highlights its substantial economic impact. Food enzymes remain a key application area within this sector. Manufacturers are increasingly adopting plant-based enzyme sources to reduce reliance on animal-derived materials, a shift supported by evolving regulatory frameworks that accommodate novel enzyme sources while ensuring safety and compliance. The adoption of sustainable production methods not only aligns with environmental goals but also provides companies with a competitive edge. Organizations that demonstrate reduced environmental impact without compromising enzyme performance are better positioned to capitalize on market opportunities. This trend is further reinforced by government initiatives aimed at promoting biotechnology innovation and sustainability, underscoring the growing importance of integrating eco-friendly practices in enzyme applications.

Stringent regulatory and safety compliance requirements

Global markets' regulatory complexities pose significant hurdles for enzyme commercialization and market entry. Manufacturers face substantial barriers due to approval processes demanding detailed safety documentation and thorough technological evaluations. The European Food Safety Authority (EFSA) has tightened guidelines for food enzymes, mandating whole genome sequencing for microorganisms and setting specific DNA detection thresholds in fermentation products. These stringent measures have driven up compliance costs and lengthened development timelines, slowing the pace of innovation. In the U.S., the FDA's Generally Recognized as Safe (GRAS) notification process has tightened. By 2024, only 13 substances secured GRAS status, marking a significant drop from prior years. This decline stems from more stringent review protocols and the increasing complexity of submissions, necessitating robust safety and technical data^{[3]Source: U.S Food and Drug Administration, "Substances securing GRAS status", fda.gov}. In China, the National Health Commission greenlit only 9 new food enzymes in 2024, despite a flood of applications. This decision underscores a global trend: a shift towards thorough safety evaluations at the expense of swift market access. Compounding these challenges, EFSA's 2021 Transparency Regulation mandates greater stakeholder engagement and public safety data disclosure. This has further stretched development timelines and escalated regulatory costs for enzyme producers. As these regulatory landscapes evolve, companies must adopt strategic approaches to adeptly navigate approval processes while upholding stringent safety compliance.

Risk of allergenic reactions from certain enzyme sources

Enzymes are proteins, and even trace residues can trigger IgE-mediated hypersensitivity in sensitive consumers or plant-floor workers according to CDC (Centers for Disease Control and Prevention). The FDA鈥檚 draft guidance on hazard analysis for dairy processors highlights enzyme carry-over as a 鈥渞easonably foreseeable hazard,鈥� instructing plants to validate preventive controls and allergen-label checks. The Consumer Healthcare Products Association recommends that dietary-supplement makers document a history of safe use and perform allergenicity assessments, including serum IgE binding studies, before commercializing any new enzyme ingredient. EFSA鈥檚 2024 enzyme dossier guidance now requires applicants to screen for known allergen motifs and provide in-silico peptide homology analyses to mitigate consumer-exposure risks. These regulatory expectations increase time-to-market and compliance costs, particularly for smaller suppliers that rely on novel microbial or plant sources without long safety records according to FDA. As a result, manufacturers must invest in rigorous purification steps, allergen labeling, and ongoing post-market surveillance to sustain consumer trust and regulatory approval according to U.S Department of Agriculture.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Lactase Leadership in Lactose-Free Solutions

In 2025, lactase enzymes hold a significant 33.62% share of the market, reflecting their critical role in driving the global dairy industry's transition to lactose-free product development. This dominance is primarily attributed to the increasing prevalence of lactose intolerance and the corresponding demand for suitable dairy alternatives. Regulatory support further strengthens this position, with the FDA's inventory of substances added to food including enzymes specifically designed for dairy applications. Additionally, the USDA's technical report on enzymes for organic food production highlights lactase's importance in reducing lactose content in dairy products, ensuring accessibility for lactose-intolerant consumers while adhering to organic certification standards. As lactase technology reaches maturity, the industry's focus has shifted towards improving enzyme stability and reducing production costs. This evolution is supported by regulatory frameworks that consistently validate the safety and efficacy of lactase in dairy processing. The segment also benefits from a well-established production infrastructure and a proven safety record, which streamline regulatory approval processes across global markets.

Microbial rennet is emerging as the fastest-growing enzyme type, with a projected CAGR of 8.33% through 2031. This growth is driven by the expanding global cheese production capacity and a rising preference for vegetarian-compatible coagulation agents. The USDA's guidance on enzymes for organic production underscores a significant shift from traditional animal-derived enzymes to microbial alternatives, aligning with consumer demand for vegetarian and organic dairy products. In 2024, China's National Health Commission approved several GMM-derived enzymes, including those relevant to dairy processing, signaling increasing regulatory acceptance of microbial enzyme technologies. Similarly, the European Food Safety Authority's Qualified Presumption of Safety (QPS) framework, established in 2005, continues to assess and update the safety of microorganisms in the food chain, supporting the development and approval of microbial rennet applications. Innovations in microbial rennet focus on enhancing purity and optimizing thermolability, which preserve whey value and address both quality and economic considerations in cheese manufacturing. These advancements position microbial rennet as a key driver of growth and innovation in the dairy enzyme market.

By Source: Microbial Dominance Through Proven Safety

In 2025, microbial sources dominate the dairy enzymes market, holding a significant 72.83% share. This leadership stems from their scalability, consistent performance, and widespread regulatory acceptance across global markets. The established fermentation infrastructure and proven safety profiles of microbial enzymes simplify regulatory approval processes, further solidifying their market position. The USDA's technical report on enzymes for organic production highlights the critical role of non-genetically modified organisms in organic systems, positioning microbial sources as a reliable alternative to animal-derived enzymes. Additionally, the European Food Safety Authority's QPS framework provides a structured methodology for assessing the safety of microorganisms used in food production. Regular updates to this framework ensure the continued development and adoption of microbial enzyme sources, reinforcing their importance in the dairy enzymes market.

Plant-based enzymes are emerging as the fastest-growing source category, with a projected CAGR of 8.12% through 2031. This growth is driven by increasing consumer demand for sustainable, vegetarian, and vegan-compatible dairy products, alongside the broader sustainability movement. The USDA's guidance on enzyme sources for organic dairy production outlines detailed requirements for plant-derived enzymes, emphasizing compliance with organic standards while maintaining their functional integrity. The European Commission's analysis of biotechnology industry competitiveness underscores the rising significance of plant-based enzyme development, supported by substantial R&D investments aimed at fostering innovation in this segment. Regulatory frameworks are evolving to accommodate these novel enzyme sources, requiring comprehensive safety and efficacy documentation to ensure consumer protection. The shift toward plant-based enzymes is particularly evident in premium and organic dairy segments, where clean-label positioning aligns with consumer preferences for ethical and sustainable food production, offering a distinct competitive advantage in the market.

By Form: Powder Stability Meets Processing Demands

In 2025, powder and granular enzyme forms dominate the market with a 59.92% share, driven by their superior storage stability, transportation efficiency, and ease of handling across diverse processing environments. These attributes make them particularly suitable for developing markets, where inadequate cold chain infrastructure necessitates shelf-stable formulations capable of withstanding temperature fluctuations during distribution. The USDA's technical report on enzymes highlights the critical role of proper handling and storage conditions in maintaining enzyme stability, with powder formulations demonstrating greater resilience compared to liquid alternatives. Additionally, the FDA's draft guidance on hazard analysis underscores the importance of optimal storage practices to prevent enzyme degradation and ensure product safety. Powder formulations remain the preferred choice for applications requiring extended storage durations, international shipping, and smaller-scale operations where liquid handling infrastructure is limited. Their ability to maintain enzyme activity over prolonged periods further solidifies their position in the market.

Conversely, liquid enzyme formulations are experiencing rapid growth, with a robust 8.05% CAGR projected through 2031. This growth is attributed to their improved handling properties, faster dissolution rates, and seamless integration into automated dairy processing systems. Liquid formulations offer distinct advantages, including reduced dust exposure, precise dosing capabilities, and the elimination of reconstitution steps that can introduce variability in enzyme activity. These features make them increasingly popular in high-volume dairy operations, where automation and precision dosing deliver significant operational efficiencies. The European Food Safety Authority's Food Enzyme Intake Model supports the safe development of both formulation types by providing tools to estimate dietary exposure to food enzymes. As processing trends evolve, liquid formulations are gaining traction in industries prioritizing efficiency and precision. Regulatory frameworks continue to adapt, ensuring both powder and liquid formulations comply with stringent safety and efficacy standards, thereby supporting their sustained growth in the market.

By Application: Cheese Manufacturing Foundation

In 2025, cheese applications dominate the dairy enzymes market with a 37.74% share, highlighting the critical role of coagulation enzymes in cheese production and the increasing global demand for cheese. This dominance is reinforced by regulatory frameworks that emphasize the importance of enzymes in traditional cheese-making processes. According to the European Union's dairy statistics, milk delivered to dairies is processed into cheese and butter, showcasing the indispensable role of enzymes in the sector. Additionally, the USDA's technical report on enzymes for organic production provides historical insights into enzyme usage in cheese-making, noting a transition toward microbial and plant-based alternatives to meet organic certification standards. Regulatory pathways for enzyme approval in cheese production are well-established, with safety assessments focusing on the characteristics of the final product and consumer exposure levels, ensuring compliance and consumer safety.

Yogurt applications are projected to be the fastest-growing segment in the dairy enzymes market, with a robust CAGR of 8.54% through 2031. This growth is driven by advancements in functional dairy innovations and increasing yogurt consumption in emerging markets. The segment's rapid expansion reflects a broader consumer shift toward functional foods and products that support digestive health. Regulatory approvals for enzyme applications that enhance product quality and nutritional value further support this trend. For instance, in October 2023, China's approval of 2'-fucosyllactose for use in infant formula underscores the growing acceptance of enzyme-derived functional ingredients, which can also be applied to yogurt formulations. Similarly, India's comprehensive regulations for infant nutrition products create opportunities for specialized enzyme applications, enabling their extension to yogurt and other fermented dairy products, thereby driving market growth.

Geography Analysis

In 2025, Europe secures a dominant 33.27% share of the dairy enzyme market, bolstered by its robust cheese manufacturing base, rigorous quality standards, and a thorough regulatory landscape. The European Dairy Association's annual report for 2024/2025 underscores the pivotal roles of innovation and sustainability in fortifying Europe's stature as a global dairy powerhouse, spotlighting value-added products and operational efficiencies. The region's dairy sector reaps benefits from the European Food Safety Authority's stringent safety evaluations for food enzymes. These evaluations mandate advanced measures, such as whole genome sequencing for microorganisms and precise DNA detection thresholds, elevating safety benchmarks and reinforcing premium market positioning.

Asia-Pacific, with an 9.34% market share in 2025, emerges as the region with the most rapid growth trajectory through 2031. This surge is fueled by rising dairy consumption, a wave of regulatory approvals, and the modernization of food safety protocols. In February 2025, China's National Health Commission greenlit 20 new food materials and additives, including 2'-fucosyllactose for infant formulas and various GMM-derived enzymes pertinent to dairy processing according to U.S Department of Agriculture. This move signals a burgeoning regulatory embrace of enzyme technologies. Meanwhile, India's Food Safety and Standards Authority has rolled out detailed regulations for infant nutrition, paving the way for specialized enzyme applications that prioritize safety and nutritional value.

South America and the Middle East & Africa stand out as burgeoning markets, propelled by a surge in dairy production and a more discerning consumer base attuned to dairy quality and functionality. Both regions are experiencing a notable uptick in cheese consumption and a gradual adoption of Western dairy habits. This shift amplifies the demand for enzyme technologies, facilitating the local production of globally favored dairy styles. However, these markets grapple with infrastructure hurdles, particularly in cold storage and distribution. Such challenges steer enzyme selection towards more stable formulations. As regulatory frameworks evolve to embrace international enzyme suppliers and technologies, there's a palpable investment in dairy processing infrastructure. This, coupled with technology transfers from seasoned markets, presents enzyme suppliers with golden opportunities. By forging strategic partnerships and establishing localized production, they can cement their foothold in these rapidly expanding regions.

Regulatory Landscape

Dairy enzyme commercialization is governed by additive or GRAS pathways in the United States and by centralized pre-market review in the European Union. In the US, enzyme preparations used in food must comply with FDA food additive regulations (including 21 CFR Part 173, Subpart B) unless they are determined to be Generally Recognized as Safe (GRAS) under the FDA GRAS framework, which frames dossier requirements around identity, manufacturing controls, and safety data for dairy applications such as lactase and cheese coagulants.

In the EU, Regulation (EC) No 1332/2008 requires that food enzymes undergo safety evaluation by the European Food Safety Authority (EFSA) and authorization by the European Commission through the common authorization procedure. The European Commission maintains a Register of Food Enzymes for applications submitted for consideration, with an update available as of February 2026, highlighting ongoing review activity and the practical value of Union-list inclusion for broad access across Member States.

Value Chain Analysis

The dairy enzymes value chain begins with strain selection and upstream inputs (microbial or plant sources), then moves through fermentation, downstream recovery and purification, formulation into powder or liquid formats, and quality and regulatory documentation to meet food-safety requirements for dairy processing. Industrial producers then supply enzymes either directly to dairy manufacturers (milk, cheese, yogurt, desserts, and infant formula applications) or via ingredient distributors that provide local technical service, dosing support, and cold-chain or stability management depending on formulation.

Activity in 2026 highlights how capacity, platform technology, and application support drive value capture across the chain. Kerry opened an expanded biotechnology manufacturing hub in Carrigaline, County Cork, to scale lactase production for lactose-free and reduced-sugar dairy, underscoring the contribution of large integrated production sites to supply assurance and consistent performance. In parallel, Dyadic Applied BioSolutions and Inzymes ApS announced planned 2026 commercialization of a recombinant non-animal bovine chymosin, reflecting increased emphasis on fermentation-derived coagulants and the way partnerships connect expression platforms and development capabilities to downstream commercialization in cheese manufacturing.

Market Opportunities and Future Outlook

Lactose-free and reduced-sugar dairy remains a key commercialization corridor for lactase suppliers, supported by visible manufacturing scale-ups and customer reach. Kerry's April 2026 opening of an expanded biotechnology manufacturing facility in Carrigaline, Ireland, focused on industrial-scale lactase production, shows where producers are investing to secure supply for global dairy processors and to support process changes that cut hydrolysis time or simplify production steps. It also opens room for formulation and application support offerings, including powder and liquid dosing, plant integration, and validation, that help dairies translate enzyme capability into throughput and quality outcomes.

Cheese is another opportunity area where fermentation-derived, non-animal coagulants and precision-fermentation approaches are being productized, aligning with clean-label and vegetarian-compatible positioning in many markets. dsm-firmenichs Maxiren EVO launch (March 2025) and the March 2026 announcement by Dyadic Applied BioSolutions and Inzymes ApS on planned 2026 commercialization of recombinant non-animal bovine chymosin point to active competition around coagulants that target specific casein fractions, improve yield, and protect whey value. Against this backdrop, structured regulatory pathways (EFSA evaluation and Commission authorization in the EU, plus FDA GRAS/food additive compliance in the US) reinforce the advantage for companies with robust dossiers, scalable fermentation, and application-centric technical service across multiple dairy categories, without relying on animal-derived enzyme supply.